68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG
Journal of Nuclear Medicine · 2024-06 · 65 (6) · 938-943
DOI: 10.2967/jnumed.123.267281 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 02.05.2024. Verfasst von Brad Kline und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Neoplasms, Positron-Emission Tomography, Radiometry. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68Ga-FAP-2286, present the first-to our knowledge-dosimetry analysis to date, and compare the agent with 18F-FDG and FAPI compounds.
Methods
Patients were administered 219 ± 43 MBq of 68Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool). Absorbed doses were evaluated using MIM Encore and OLINDA/EXM version 1.1 using the International Commission on Radiological Protection publication 103 tissue weighting factor.
Results
Forty-six patients were imaged with 68Ga-FAP-2286 PET. The highest average uptake was seen in sarcoma, cholangiocarcinoma, and colon cancer. The lowest uptake was found in lung cancer and testicular cancer. The average SUVmax was significantly higher on 68Ga-FAP-2286 PET than on 18F-FDG PET in cholangiocarcinoma (18.2 ± 6.4 vs. 9.1 ± 5.0, P = 0.007), breast cancer (11.1 ± 6.8 vs. 4.1 ± 2.2, P < 0.001), colon cancer (13.8 ± 2.2 vs. 7.6 ± 1.7, P = 0.001), hepatocellular carcinoma (9.3 ± 3.5 vs. 4.7 ± 1.3, P = 0.01), head and neck cancer (11.3 ± 3.5 vs. 7.6 ± 5.5, P = 0.04), and pancreatic adenocarcinoma (7.4 ± 1.8 vs. 3.7 ± 1.0, P = 0.01). The total-body effective dose was estimated at 1.16E-02 mSv/MBq, with the greatest absorbed organ dose in the urinary bladder wall (9.98E-02 mGy/MBq).
Conclusion
68Ga-FAP-2286 biodistribution, dosimetry, and tumor uptake were similar to those of previously reported FAPI compounds. Additionally,68Ga-FAP-2286 PET had consistently higher uptake than 18F-FDG PET. These results are especially promising in the setting of small-volume disease and differentiating tumor from inflammatory uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
- Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
- Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
- Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California; and.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Kline, B., Yadav, S., Seo, Y., Ippisch, R. C., Castillo, J., Aggarwal, R. R., Kelley, R. K., Behr, S. C., Flavell, R. R., Lawhn-Heath, C., Melisko, M., Rugo, H. S., Wang, V., Yom, S. S., Ha, P., Jiang, F., & Hope, T. A. (2024). 68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG. Journal of Nuclear Medicine, 65(6), 938-943. https://doi.org/10.2967/jnumed.123.267281
Vancouver
Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, et al. 68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG. Journal of Nuclear Medicine. 2024;65(6):938-943. doi:10.2967/jnumed.123.267281
BibTeX
@article{Kline2024,
author = {Kline, Brad and Yadav, Surekha and Seo, Youngho and Ippisch, Robin Cumming and Castillo, Jessa and Aggarwal, Rahul R and Kelley, Robin Kate and Behr, Spencer C and Flavell, Robert R and Lawhn-Heath, Courtney and Melisko, Michelle and Rugo, Hope S and Wang, Victoria and Yom, Sue S and Ha, Patrick and Jiang, Fei and Hope, Thomas A},
title = {68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {6},
pages = {938--943},
doi = {10.2967/jnumed.123.267281}
}
EUVIMED